Focus on what matters

QIAGEN’s FDA approved therascreen® EGFR RGQ PCR Kit now detects even more clinically validated mutations
It is crucial to target mutations that have the most clinical value

QIAGEN® understands the importance of identifying and targeting mutations of clinical interest for non-small cell lung cancer (NSCLC) patients. With the recent approval of GILOTRIF® to treat patients with additional EGFR mutations, our therascreen EGFR test now covers even more clinically validated mutations than any other commercially available PCR-based assay.

Clinically actionable information is what helps treat patients

Focus on what really matters when testing for EGFR mutations, to make the best therapeutic decisions

Detect more clinically validated mutations

- **Focus on what matters**: QIAGEN helps oncologists interpret data by focusing on mutations that are clinically relevant.
- **Our therascreen EGFR test detects more clinically validated mutations than any other commercially available PCR-based test**:
  - 18 clinically validated EGFR mutations (vs. 11 from test c)
  - 21 analytically validated EGFR mutations (vs. 19 from test c)†*

Proven NSCLC solutions

- **FDA approved**: QIAGEN’s therascreen EGFR test has been clinically validated and is approved for use with two major lung cancer therapies: IRESSA® and GILOTRIF
- **Versatile and complete solutions**: QIAGEN’s complete Sample to Insight workflow includes a wide range of molecular tools and user friendly software to address various needs of oncology testing laboratories

Ordering Information

<table>
<thead>
<tr>
<th>Product</th>
<th>Contents</th>
<th>Cat. no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>therascreen EGFR RGQ PCR Kit</td>
<td>For 24 reactions: 1 Control, 7 Mutation Assays, Positive Control, Taq DNA Polymerase, Water</td>
<td>870121</td>
</tr>
</tbody>
</table>

Learn more at www.qiagen.com/therascreen